
Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2011 | 0 | 2.965.749 | 279.600 | 1 | ||
| 2010 | 0 | 5.998.757 | 303.528 | 1 | ||
Total number of partners: 2661
Partner loyalty:
Frequent Partner: (> 2 projects): 1218
Rare Partner: 1443
Frequent / Rare Partner Ratio: 0.84
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2011-01-01 | Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis | CURELUNG | participant | 2.965.749 | 11 |
| 2010-11-01 | New drugs targeting influenza virus polymerase | FLU-PHARM | participant | 5.998.757 | 12 |